Jorge Di Paola

List of Publications by Year
in descending order

81 papers	2,850 citations	236925 25 h-index	182427 51 g-index
82 all docs	82 docs citations	82 times ranked	3624 citing authors

#	Article	IF	Citations
1	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances, 2022, 6, 420-428.	5.2	4
2	Isotopically nonstationary 13C metabolic flux analysis in resting and activated human platelets. Metabolic Engineering, 2022, 69, 313-322.	7.0	10
3	Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels. Blood, 2022, 139, 2240-2251.	1.4	9
4	Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program. Journal of Thrombosis and Haemostasis, 2022, 20, 1576-1588.	3.8	5
5	Genetics of inherited thrombocytopenias. Blood, 2022, 139, 3264-3277.	1.4	10
6	Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength. Platelets, 2022, 33, 1119-1131.	2.3	5
7	ETV6-related thrombocytopenia and platelet dysfunction. Platelets, 2021, 32, 141-143.	2.3	4
8	Platelet activation contributes to hypoxia-induced inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L413-L421.	2.9	21
9	Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel. Blood Advances, 2021, 5, 414-431.	5.2	19
10	von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. Blood, 2021, 137, 3277-3283.	1.4	8
11	Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 35, 102405.	3.3	2
12	Diagnostic approach to the patient with a suspected inherited platelet disorder: Who and how to test. Journal of Thrombosis and Haemostasis, 2021, 19, 2127-2136.	3.8	5
13	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Advances, 2021, 5, 5023-5031.	5.2	6
14	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
15	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
16	Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica, 2020, 105, 585-597.	3.5	32
17	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
18	Platelet Î±-granules are required for occlusive high-shear-rate thrombosis. Blood Advances, 2020, 4, 3258-3267.	5.2	11

#	Article	IF	Citations
19	Hypermethioninemia Leads to Fatal Bleeding and Increased Mortality in a Transgenic I278T Mouse Model of Homocystinuria. Biomedicines, 2020, 8, 244.	3.2	5
20	Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24316-24325.	7.1	33
21	Pathologic Shear and Elongation Rates Do Not Cause Cleavage of Von Willebrand Factor by ADAMTS13 in a Purified System. Cellular and Molecular Bioengineering, 2020, 13, 379-390.	2.1	9
22	Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica, 2020, 105, 888-894.	3.5	75
23	ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight, 2020, 5, .	5.0	15
24	TNF-Î±â€“driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood, 2019, 134, 727-740.	1.4	199
25	Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and) Tj ETQq1 1 0.784314 rgBT /Ove Vascular Biology, 2019, 39, 1831-1842.	2.4	36
26	ETV6-related thrombocytopenia and leukemia predisposition. Blood, 2019, 134, 663-667.	1.4	45
27	Behavior, body composition, and vascular phenotype of homocystinuric mice on methionineâ€restricted diet or enzyme replacement therapy. FASEB Journal, 2019, 33, 12477-12486.	0.5	16
28	Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 607-617.	3.8	12
29	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	1.4	32
30	Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Research, 2019, 47, e20-e20.	14.5	16
31	Chitinase 3â€like1 promotes intrahepatic activation of coagulation through induction of tissue factor in mice. Hepatology, 2018, 67, 2384-2396.	7.3	15
32	Effects of antiâ€Î²2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 380-389.	2.3	10
33	Antiplatelet Effect of Ketorolac in Children After Congenital Cardiac Surgery. World Journal for Pediatric & Congenital Heart Surgery, 2018, 9, 651-658.	0.8	5
34	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	5.2	79
35	von Willebrand Disease. Pediatric Clinics of North America, 2018, 65, 527-541.	1.8	11
36	A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. PLoS ONE, 2018, 13, e0200917.	2.5	45

#	Article	IF	Citations
37	GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. Frontiers in Medicine, 2018, 5, 137.	2.6	36
38	NBEAL2 mutations and bleeding in patients with gray platelet syndrome. Platelets, 2018, 29, 632-635.	2.3	29
39	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. Blood, 2018, 132, 979-979.	1.4	1
40	Genotypic and Phenotypic Analysis of Adolescents with Heavy Menstrual Bleeding and Low Von Willebrand Activity - Interim Report of a Multi-Center Study. Blood, 2018, 132, 984-984.	1.4	2
41	Epigenetic Profiles of Primary Endothelial Cells from Patients with Low VWF Levels. Blood, 2018, 132, 983-983.	1.4	2
42	Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality. Blood, 2018, 132, 2573-2573.	1.4	1
43	Single Cell RNA Sequencing of Blood Outgrowth Endothelial Cells from Patients with Low Von Willebrand Factor Reveal Multiple Novel Signaling Pathways. Blood, 2018, 132, 982-982.	1.4	0
44	TNF-Î± Driven Inflammation and Mitochondrial Dysfunction Characterize the Platelet Hyperreactivity of Aging and Myeloproliferative Neoplasms (MPN). Blood, 2018, 132, 1134-1134.	1.4	10
45	Tamoxifen Suppresses Platelet Activation-Supported Angiogenesis and Metastasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 611-612.	2.4	6
46	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	1.4	98
47	Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. Scientific Reports, 2017, 7, 4275.	3.3	14
48	Variable bleeding phenotype in an Amish pedigree with von Willebrand disease. American Journal of Hematology, 2016, 91, E431-5.	4.1	2
49	Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nature Communications, 2016, 7, 12863.	12.8	87
50	Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice. PLoS ONE, 2016, 11, e0150852.	2.5	13
51	Novel Congenital Platelet Disorders. Blood, 2016, 128, SCI-39-SCI-39.	1.4	0
52	Diagnostic approach to von Willebrand disease. Blood, 2015, 125, 2029-2037.	1.4	148
53	Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood, 2015, 126, 262-269.	1.4	16
54	Paris-Trousseau: evidence keeps pointing to FLI1. Blood, 2015, 126, 1973-1974.	1.4	5

#	Article	IF	Citations
55	Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. Thrombosis Research, 2015, 136, 13-19.	1.7	59
56	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics, 2015, 47, 535-538.	21.4	274
57	Genetic basis of congenital platelet disorders. Hematology American Society of Hematology Education Program, 2014, 2014, 337-342.	2.5	4
58	A novel mutation in PLP1 causes severe hereditary spastic paraplegia type 2. Gene, 2014, 533, 447-450.	2.2	9
59	Factor XIII activity mediates red blood cell retention in venous thrombi. Journal of Clinical Investigation, 2014, 124, 3590-3600.	8.2	165
60	Evaluating Familial Essential Tremor with Novel Genetic Approaches: Is it a Genotyping or Phenotyping Issue?. Tremor and Other Hyperkinetic Movements, 2014, 4, 258.	2.0	4
61	Understanding congenital platelet disorders. Clinical Advances in Hematology and Oncology, 2014, 12, 461-3.	0.3	0
62	Tissue Factor Signals Airway Epithelial Basal Cell Survival via Coagulation and Protease-Activated Receptor Isoforms 1 and 2. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 94-104.	2.9	21
63	New developments in the treatment of pediatric hemophilia and bleeding disorders. Current Opinion in Pediatrics, 2013, 25, 23-30.	2.0	6
64	SHPing in different directions in platelet production. Blood, 2013, 121, 4018-4019.	1.4	2
65	SNP Analysis Of The VWF GENE Identifies Multiple Common Variants THAT Affect VWF Levels and OCCUR At Different Frequencies In Patients With TYPE 1 VWD. Blood, 2013, 122, 334-334.	1.4	0
66	Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: Implications for identifying coagulopathic mechanisms in humans. Thrombosis and Haemostasis, 2012, 108, 516-526.	3.4	14
67	The ASPHO Meeting (25 Years of Excellence). Pediatric Blood and Cancer, 2012, 58, 1098-1098.	1.5	0
68	Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nature Genetics, 2011, 43, 738-740.	21.4	239
69	Homozygosity mapping with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the interval significantly. Blood, 2011, 117, 3430-3434.	1.4	25
70	The ASPHO Meeting. Pediatric Blood and Cancer, 2011, 56, 974-974.	1.5	0
71	Thrombocytopenias Due to Gray Platelet Syndrome orTHC2Mutations. Seminars in Thrombosis and Hemostasis, 2011, 37, 690-697.	2.7	29
72	Recombinant Factor IX for Clinical and Research Use. Seminars in Thrombosis and Hemostasis, 2010, 36, 498-509.	2.7	32

#	Article	IF	Citations
73	Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood, 2008, 111, 1257-1265.	1.4	189
74	PACAP: a new player in thrombopoiesis. Blood, 2008, 111, 1753-1754.	1.4	0
75	VWD type 1: a calculated diagnosis. Blood, 2008, 111, 3919-3920.	1.4	0
76	Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagulation and Fibrinolysis, 2008, 19, 276-282.	1.0	53
77	The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood, 2005, 105, 518-525.	1.4	83
78	Role of FcRÎ³ and factor XIIIA in coated platelet formation. Blood, 2005, 106, 4146-4151.	1.4	43
79	Product selection issues in the management of hemophilia B. Blood Coagulation and Fibrinolysis, 2004, 15, S17-S18.	1.0	4
80	Deep Venous Thrombosis and Turner Syndrome. Journal of Pediatric Hematology/Oncology, 2004, 26, 272.	0.6	10
81	Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood, 2002, 100, 2839-2844.	1.4	22